Introduction: The European Working Group on Sarcopenia in Older People (EWGSOP2) defines sarcopenia as a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age. New findings on the hormonal and metabolic characteristics of patients with sarcopenia have aided in developing more targeted therapeutic strategies. However, treating older patients with sarcopenia still poses a number of challenges.
View Article and Find Full Text PDFBackground: Developing countries have partnered with non-governmental and development organizations to ensure universal health coverage and promote equity in accessing health services. This study was motivated by the timely and relevant collaborative partnership among the National Primary Health Care Development Agency (NPHCDA), Sydani Consulting, and other implementing partners at the sub-national level. There is also no evidence of a study on partnership coordination vis-à-vis COVID-19 vaccine optimization.
View Article and Find Full Text PDFHow patient and tumor factors influence clearance margins and the number of Mohs Micrographic Surgery (MMS) stages when treating basal cell carcinoma (BCC) remains widely uncharacterized. It is important to elucidate these relationships, as surgical outcomes may be compared nationally between colleagues. Our objective is to evaluate the relationships between defect size and patient demographics, as well as between BCC subtypes and the number of MMS stages.
View Article and Find Full Text PDF